Possible testing includes: A CMP or BMP when vomiting, diarrhea, poor fluid intake, or kidney risk is present Glucose review in people with diabetes A1C testing after enough time has passed to reflect a meaningful glycemic trend Additional tests based on previous abnormalities or new symptoms Stable Long-Term Monitoring A1C monitoring should follow the patient's diabetes status and treatment goals
A new paper published in The Lancet analyzed data from a key clinical trial for semaglutide (brand name Ozempic/Wegovy)
Table 2 FDA-Approved Dosages and Indications for GLP-1 and Dual GIP/GLP-1 Receptor Agonists
Nausea is one of the most frequently reported side effects, affecting approximately 50% of patients taking GLP-1 medications, whilst vomiting occurs in about 15-25% of patients
Many Plans Exclude Weight-Loss Drugs Many Anthem insurance plans explicitly exclude Wegovy and other weight loss medications
The law prohibits retailers from selling the product while allowing limited exceptions for medical, dental, and food-related uses
